Skip to content

FEES to Determine Neurological Intensive Care Patients' Oral Diet

Flexible Endoscopic Evaluation of Swallowing (FEES) to Determine Neurological Patients' Oral Diet

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03753841
Enrollment
125
Registered
2018-11-27
Start date
2014-01-14
Completion date
2016-09-16
Last updated
2018-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aspiration Pneumonia, Deglutition Disorders, Dysphagia, Intensive Care Neurological Disorder

Keywords

Dysphagia, Aspiration, Management of Dysphagia, Deglutition Disorders, Deglutition, FEES, Intensive Care Neurological Disorder

Brief summary

Dysphagia is associated with high rates of mortality and morbidity. Adjusting the oral diet of ICU-patients based on flexible endoscopic evaluation of swallowing (FEES) findings might reduce pneumonia rate, mortality and need for intubation/tracheotomy.

Detailed description

Dysphagia, a common complication in neurological disorders, leads to high rates of mortality and morbidity. It is prevalent in critically ill patients, especially those who need mechanical ventilation. The investigators therefore investigate the effect of adjusting the oral diet of our intensive care unit (ICU) patients based on flexible endoscopic evaluation of swallowing (FEES) findings, thereby assessing the impact of FEES on a neurological ICU. All patients treated on the investigators neurological ICU will be eligible for this study. The investigators will correlate findings with baseline data, disability status, pneumonia and duration of hospitalisation, as well as a need for mechanical ventilation or a tracheotomy.

Interventions

OTHERAdjustment of oral diet

Adjustment of oral diet based on findings in fiberendoscopic evaluation of swallowing (FEES)

Sponsors

University of Giessen
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Treatment on neurological ICU * Clinical suspicion of Dysphagia

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
Pneumonia RateUp to 130 daysself-explanatory
MortalityUp to 130 daysself-explanatory

Secondary

MeasureTime frameDescription
Length of stay in hospitalUp to 130 daysself-explanatory
Intubation/TracheotomyUp to 130 daysRate of Intubation/Tracheotomy

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026